abemaciclib – Medxy AI

Neoadjuvant Abemaciclib plus Letrozole: A Potential Chemotherapy-Sparing Strategy in Select HR+/HER2- Breast Cancers?

By MedXY 01/11/2026

The CARABELA trial suggests that while neoadjuvant abemaciclib plus letrozole did not meet the threshold for similarity to chemotherapy in highly proliferative HR+/HER2- breast cancer, it remains a viable alternative for patients with lower genomic risk or moderate proliferation indices.

news Oncology

Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer

By MedXY 01/09/2026

The Phase II TRADE trial demonstrates that a stepwise dose escalation of abemaciclib significantly improves drug tolerability and reduces early discontinuation rates in patients with high-risk HR-positive, HER2-negative early breast cancer compared to standard initiation protocols.

news Oncology Urology

Abemaciclib plus Abiraterone Fails to Improve rPFS in mCRPC: Lessons from the CYCLONE 2 Phase 3 Trial

By MedXY 11/05/2025

The phase 3 CYCLONE 2 trial found that adding the CDK4/6 inhibitor abemaciclib to abiraterone did not significantly prolong radiographic progression‑free survival in men with metastatic castration‑resistant prostate cancer and increased toxicity, including treatment‑related interstitial lung disease.